natgillin/translations-raw huggingface dataset:
How to store Seroquel
Moguće nuspojave Kako čuvati Seroquel
Dysarthria
Disfagija
Each tablet contains 400 mg quetiapine (as fumarate)
Jedna tableta sadrži 400 mg kvetiapina (u obliku kvetiapinfumarata).
INFORMATION IN BRAILLE Seroquel XR 50 mg
16. PODACI NA BRAILLEOVOM PISMU Seroquel XR 50 mg
Each tablet contains 300 mg quetiapine (as fumarate)
Jedna tableta sadrži 300 mg kvetiapina (u obliku kvetiapinfumarata).
• A long-lasting and painful erection (priapism).
• dugotrajnu i bolnu erekciju (prijapizam)
Drug withdrawal syndrome neonatal31
babinje i perinatalno razdoblje sindrom ustezanja kod novorođenčadi31
6 blisters of 10 tablets
6 blistera s 10 tableta
The 25 mg, 100 mg and 150 mg tablet also contain iron oxide yellow (E172) and the 25 mg contain iron oxide red (E172).
150 mg također sadrže žuti željezov oksid (E 172), a tablete od 25 mg sadrže i crveni željezov oksid
Each tablet contains 150 mg quetiapine (as fumarate)
Jedna tableta sadrži 150 mg kvetiapina (u obliku kvetiapinfumarata).
(See also section 4.5)
(vidjeti i dio 4.8).
Seroquel 150 mg contains 150 mg quetiapine (as quetiapine fumarate) Excipient : 29 mg lactose (anhydrous) per tablet
Seroquel 150 mg sadržava 150 mg kvetiapina (u obliku kvetiapinfumarata).
Seroquel XR 150 mg and 300 mg/day, given as add-on treatment to ongoing antidepressant therapy (amitriptyline, bupropion, citalopram, duloxetine, escitalopram, fluoxetine, paroxetine, sertraline or venlafaxine) demonstrated superiority over antidepressant therapy alone in reducing depressive symptoms as measured by improvement in MADRS total score (LS mean change vs. placebo of 2-3.3 points).
Seroquel XR 150 mg i 300 mg/dnevno, primijenjen kao dodatna terapija uz postojeću terapiju antidepresivima (amitriptilin, bupropion, citalopram, duloksetin, escitalopram,
NAME OF THE MEDICINAL PRODUCT Seroquel 25 mg, 100 mg and 200 mg film-coated tablets quetiapine
Seroquel 25 mg, 100 mg i 200 mg filmom obložene tablete kvetiapin
• If you are taking any of the following medicines: - some medicines for HIV - azole medicines (for fungal infections) - erythromycin or clarithromycin (for infections) - nefazodone (for depression)
- neke lijekove kojima se liječi HIV - lijekove iz skupine azola (za suzbijanje gljivičnih infekcija)
(13) Platelets ≤100 x 10
13. Barem jednom izmjerena vrijednost trombocita ≤ 100 x 109/L
• Bowel obstruction.
• upala gušterače.
10 blisters of 10 tablets
10 blistera s 10 tabletsa
For patients who were randomized to placebo, the mean weight gain during the open label period was 2.39 kg, and by week 48 of the randomized period the mean weight gain was 0.89 kg, compared to open label baseline.
Za bolesnike koji su randomizirani u skupinu s placebom srednji dobitak na težini tijekom otvorenog razdoblja ispitivanja bio je 2,39 kg, a do
Iron oxide, yellow (E172) (50, 200 and 300 mg tablets) Iron oxide, red (E172) (50 mg tablets) 6.2 Incompatibilities
Ovojnica hipromeloza 2910 makrogol 400 titanijev dioksid (E 171) željezov oksid, žuti (E 172) (tablete od 50 mg, 200 mg i 300 mg) željezov oksid, crveni (E 172) (tablete od 50 mg).
Quetiapine should be used with caution in patients with known cardiovascular disease, cerebrovascular disease, or other conditions predisposing to hypotension.
Kvetiapin se mora davati s oprezom bolesnicima za koje je poznato da imaju kardiovaskularne bolesti,
Seroquel XR 200 mg prolonged-release tablets quetiapine
Seroquel XR 200 mg tablete s produljenim oslobađanjem kvetiapin
Renal Impairment: Dosage adjustment is not necessary in patients with renal impairment.
U bolesnika s oštećenom funkcijom bubrega nije potrebna prilagodba doze.
Reproductive system and breast disorders
Poremećaji bubrega i mokraćnog sustava retencija mokraće
INFORMATION IN BRAILLE Seroquel XR 300 mg
16. PODACI NA BRAILLEOVOM PISMU Seroquel XR 300 mg
Use in children and adolescents Seroquel should not be used by children and adolescents aged under 18 years.
Seroquel ne smiju koristiti djeca i adolescenti mlađi od 18 godina.
Seroquel 100 mg contains 100 mg quetiapine (as quetiapine fumarate) Excipient : 20 mg lactose (anhydrous) per tablet
Seroquel 100 mg sadržava 100 mg kvetiapina (u obliku kvetiapinfumarata).
The frequencies of adverse events are ranked according to the following: Very common (≥1/10), common
Nuspojave povezane s liječenjem kvetiapinom Učestalost nuspojava klasificirana je na sljedeći način: vrlo često (>1/10), često (>1/100 i <1/10),
Seroquel XR 150 mg prolonged-release tablets quetiapine
Seroquel XR 150 mg tablete s produljenim oslobađanjem kvetiapin
Seroquel 200 mg contains 200 mg quetiapine (as quetiapine fumarate) Excipient : 39 mg lactose (anhydrous) per tablet
Seroquel 200 mg sadržava 200 mg kvetiapina (u obliku kvetiapinfumarata).
Gradual withdrawal over a period of at least one to two weeks is advisable.
Preporuča se postupno prekidanje uzimanja lijeka tijekom perioda od najmanje jednog do dva tjedna (vidjeti dio 4.8.).
Each tablet contains 50 mg quetiapine (as fumarate)
Jedna tableta sadrži 50 mg kvetiapina (u obliku kvetiapinfumarata).
o Men and women to have swelling of breasts and unexpectedly produce breast milk.
• oticanje dojki i neočekivano izlučivanje mlijeka iz dojki kod muškaraca i žena.
How to store Seroquel XR
Moguće nuspojave Kako čuvati Seroquel XR
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER FOIL 3-Day starter pack
FOLIJA BLISTERA 3-dnevno početno pakiranje
• If you get any side effects talk to your doctor or pharmacist.This includes any side effects not listed in this leaflet.
Navedeni učinci se smatraju svojstvenima svim lijekovima ove farmakološke skupine (učinak klase), a ne nekom njezinom pojedinačnom predstavniku.
In two recurrence prevention studies evaluating quetiapine in combination with mood stabilizers, in patients with manic, depressed or mixed mood episodes, the combination with quetiapine was superior to mood stabilizers monotherapy in increasing the time to recurrence of any mood event (manic, mixed or depressed).
Provedena su dva ispitivanja u kojima se procjenjivao kvetiapin korišten u kombinaciji sa stabilizatorima raspoloženja u svrhu sprječavanja ponovne pojave bolesti, u bolesnika s maničnim, depresivnim ili mješovitim epizodama.
MINIMUM PARTICULARS TO APPEAR ON BLISTERS OR STRIPS BLISTER FOIL 4-Day starter pack
FOLIJA BLISTERA 4-dnevno početno pakiranje
Seroquel XR 50 mg prolonged-release tablets quetiapine
Seroquel XR 50 mg tablete s produljenim oslobađanjem kvetiapin
Seroquel XR 300 mg prolonged-release tablets quetiapine
Seroquel XR 300 mg tablete s produljenim oslobađanjem kvetiapin
3 blisters of 10 tablets
3 blistera s 10 tableta
Seizures:
Spol:
Seroquel 300 mg contains 300 mg quetiapine (as quetiapine fumarate) Excipient : 59 mg lactose (anhydrous) per tablet
Seroquel 300 mg sadržava 300 mg kvetiapina (u obliku kvetiapinfumarata).
Seroquel XR 400 mg prolonged-release tablets quetiapine
Seroquel XR 400 mg tablete s produljenim oslobađanjem kvetiapin
Tardive Dyskinesia:
ROK VALJANOSTI Rok valjanosti:
Cataracts/lens opacities
Katarakta / zamućenje leće
If you take more Seroquel than prescribed by your doctor, you may feel sleepy, feel dizzy and experience abnormal heart beats.
Vam je propisao liječnik, možete osjetiti pospanost, omaglicu i nepravilne otkucaje srca.
Agranulocytosis26
povećanja razine TSH24
Seroquel tablets contain 25 mg, 100 mg, 150 mg, 200 mg or
Seroquel tablete sadrže 25 mg, 100 mg, 150 mg,200 mg ili 300 mg kvetiapina (u obliku kvetiapinfumarata).
SOC
U
At steady-state, the dosenormalized plasma levels of the parent compound, quetiapine, in children and adolescents (10-17 years of age) were in general similar to adults, though Cmax in children was at the higher end of the range observed in adults.
(10-17 godina) uglavnom je bila slična onoj u odraslih, iako je Cmax u djece bio na gornjoj granici raspona zabilježenog u odraslih.
Macrogol 400
P450.
NAME OF THE MEDICINAL PRODUCT Seroquel 25 mg and 100 mg film-coated tablets quetiapine
Seroquel 25 mg i 100 mg filmom obložene tablete kvetiapin
In 4 clinical trials with a duration of 8 weeks in patients with moderate to severe depressive episodes in bipolar I or bipolar II disorder, Seroquel IR 300 mg and 600 mg was significantly superior to placebo treated patients for the relevant outcome measures: mean improvement on the MADRS and for response defined as at least a 50% improvement in MADRS total score from baseline.
Seroquel tablete s trenutnim oslobađanjem od 300 mg i 600 mg su se pokazale značajno superiornije od placeba u relevantnim mjerama ishoda: srednjem poboljšanju na MADRS ljestvici i odgovoru definiranom kao najmanje 50% poboljšanja u ukupnom MADRS zbroju bodova u odnosu na početni rezultat.
In some cases, a prior increase in body weight has been reported which may be a predisposing factor.Appropriate clinical monitoring is advisable in accordance with utilised antipsychotic guidelines.
Povećanje tjelesne težine je bilo prijavljeno kod bolesnika koji su liječeni kvetiapinom, i mora se nadzirati i zbrinjavati kako je klinički prikladno, u skladu sa smjernicama za primjenu antipsihotika (vidjeti dijelove
4 See section 5.1
4.8 i 5.1).
Dizziness 4, 16, somnolence headache, Extrapyramidal symptoms1, 21
Poremećaji živčanog sustava omaglica somnolencija2, 16, glavobolja, ekstrapiramidni simptomi dizartrija
• If you are taking any of the following medicines: o some medicines for HIV o azole medicines (for fungal infections) o erythromycin or clarithromycin (for infections) o nefazodone (for depression).
• neke lijekove za liječenje HIV-a, • lijekove iz skupine azola (za suzbijanje gljivičnih infekcija),
9/L on at least one occasion (14) Based on clinical trial adverse event reports of blood creatine phosphokinase increase not associated with neuroleptic malignant syndrome (15) Prolactin levels (patients >18 years of age): >20 μg/L (>869.56 pmol/L) males; >30 μg/L (>1304.34 pmol/L) females at any time.
Opći poremećaji i reakcije na mjestu primjene razdražljivost3 Razina prolaktina (bolesnici < 18 godina) u bilo kojem trenutku: > 20 µg/L (> 869,56 pmol/L) muškarci; > 26
Endocrine disorders
Organski sustav
Uncommon side effects (may affect up to 1 in 100 people):
Manje česte nuspojave (mogu se javiti u do 1 na 100 osoba): • napadaji
Seroquel 300 mg film-coated tablets are white, capsule-shaped and engraved with SEROQUEL on one side and 300 on the other side
Seroquel 300 mg filmom obložene tablete su bijele boje, u obliku kapsule.
Rhinitis
Cipar
• Fits (seizures).
Area Under Curve).
Renal and urinary disorders
prsišta i sredoprsja rinitis
Hyponatraemia 19, Diabetes Mellitus
Krvožilni poremećaji ortostatska hipotenzija4, 16
Quetiapine exhibits minimal dystonic liability in haloperidol-sensitised or drug-naive Cebus monkeys after acute and chronic administration.
Ograničeni su podaci o primjeni kvetiapina u kombinaciji s divalproeksom ili litijem u akutnom liječenju umjerenih do teških maničnih epizoda.
In clinical studies of patients with MDD the incidence of suicide-related events observed in young adult patients (younger than 25 years of age) was 2.1% (3/144) for quetiapine and 1.3% (1/75) for placebo.
godina) bila je 2,1% (3/144) za kvetiapin i 1,3% (1/75) za placebo.
The usual effective dose is in the range of 400 to 800 mg/day.
Uobičajena učinkovita doza se kreće u rasponu od 400
The pharmacokinetics of quetiapine and norquetiapine are linear and dose-proportional for doses up to 800 mg administered once daily.
Pri primjeni lijeka u jednokratnim dnevnim dozama do najviše 800 mg, farmakokinetika kvetiapina i norkvetiapina linearna je i razmjerna dozi.
Responder rates (YMRS improvement ≥50%) were 64% for Seroquel 400 mg/day, 58% for 600 mg/day and 37% in the placebo arm.
Stopa odgovora (YMRS poboljšanje ≥ 50%) bila je 64% za Seroquel 400
This summary was last updated in 11-2014.
Ovaj sažetak je posljednji put ažuriran u 11.2014.
In addition, Trulicity has the advantage of being given once a week.
Nadalje, Trulicity ima prednost primjene jednom tjedno.
Trulicity dulaglutide
Trulicity dulaglutid
Information from a sixth study that was submitted during the procedure was also considered.
U obzir su uzete i informacije iz šestog ispitivanja koje su dostavljene tijekom postupka.
The full EPAR and risk management plan summary for Trulicity can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Cjeloviti EPAR kao i sažetak plana upravljanja rizikom za lijek Trulicity nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The European Commission granted a marketing authorisation valid throughout the European Union for Trulicity on 21 November 2014.
Europska komisija izdala je odobrenje za stavljanje u promet koje je za lijek Trulicity na snazi u Europskoj uniji od 21. studenog 2014.
Other information about Trulicity
Ostale informacije o lijeku Trulicity
This is a summary of the European public assessment report (EPAR) for Trulicity.
Ovo je sažetak europskoga javnog izvješća o ocjeni dokumentacije (EPAR) o lijeku Trulicity.
With respect to safety, effects of longer term use and safety in vulnerable groups such as the very elderly would need to be monitored, but there were no specific areas of major concern and the risks were considered similar to those of other medicines in its class.
Vezano uz sigurnu primjenu, djelovanje dugoročne primjene i sigurnost u osjetljivih skupina poput primjerice vrlo starih osoba potrebno je pratiti, no nema specifičnih područja veće zabrinutosti, a zaključeno je da su rizici slični onima drugih lijekova iste klase.
It is not intended to provide practical advice on how to use Trulicity.
Svrha sažetka nije davati praktične savjete o korištenju lijeka Trulicity.
Why is Trulicity approved?
Zašto je Trulicity odobren?
What measures are being taken to ensure the safe and effective use of Trulicity?
Koje se mjere poduzimaju kako bi se osigurala sigurna i učinkovita primjena lijeka Trulicity?
Patients inject the medicine themselves (after suitable training) under the skin in the abdomen or thigh.
Bolesnici sami ubrizgavaju lijek (nakon primjerene obuke) potkožno u abdomen ili bedro.
The Agency's Committee for Medicinal Products for Human Use (CHMP) decided that Trulicity's benefits are greater than its risks and recommended that it be approved for use in the EU.
Odbor za lijekove za humanu uporabu (CHMP) pri Agenciji odlučio je da koristi od lijeka Trulicity nadmašuju s njim povezane rizike te je preporučio njegovo odobrenje za korištenje u Europskoj uniji.
The benefits of Trulicity have been studied in 5 main studies involving over 4,500 patients with type 2 diabetes.
Koristi lijeka Trulicity ispitane su u 5 glavnih ispitivanja koja su obuhvatila više od 4 500 bolesnika s dijabetesom tipa 2.
The most common side effects with Trulicity (which may affect more than 1 in 10 people) are nausea (feeling sick), vomiting and diarrhoea.
Najčešće nuspojave lijeka Trulicity (mogu se javiti u više od 1 na 10 osoba) su mučnina (osjećaj slabosti), povraćanje i proljev.
A risk management plan has been developed to ensure that Trulicity is used as safely as possible.
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Trulicity.
The Committee noted that the medicine produces a significant and clinically relevant effect in controlling blood glucose when used with other medicines.
Odbor je zaključio da lijek ima značajan i klinički relevantan utjecaj na kontroliranje razina glukoze u krvi ako se koristi s drugim lijekovima.
This was considered to be clinically meaningful and there was evidence that the benefits were maintained during long-term treatment.
Zaključeno je da je ovo klinički značajno smanjenje, te da postoji dokaz da su koristi održane tijekom dugotrajnog liječenja.
What is Trulicity and what is it used for?
Što je Trulicity i za što se koristi?
The patients' average HbA1c at baseline ranged from 7.6 to 8.5% and patients were treated for at least 52 weeks.
Prosječna razina HbA1c u bolesnika na početku liječenja bila je u rasponu od 7,6 do 8,5 %, a bolesnici su liječeni najmanje 52 tjedna.
The active substance in Trulicity, dulaglutide, is a ‘GLP-1 receptor agonist'.
Djelatna tvar lijeka Trulicity, dulaglutid, je „agonist GLP-1 receptora”.
HbA1c gives an indication of how well the blood glucose is controlled.
HbA1c ukazuje na to koliko se dobro kontrolira razina glukoze u krvi.
The main measure of effectiveness was the change in the level of glycosylated haemoglobin (HbA1c), which is the percentage of haemoglobin in the blood that has glucose attached.
Glavno mjerilo djelotvornosti bila je promjena u razini glikoziliranog hemoglobina (HbA1c), što predstavlja postotak hemoglobina u krvi na koji se vezuje glukoza.
What are the risks associated with Trulicity?
Koji su rizici povezani s lijekom Trulicity?
When Trulicity is injected, dulaglutide reaches the receptors in the pancreas and activates them.
Prilikom ubrizgavanja lijeka Trulicity, dulaglutid dolazi do receptora u gušterači i aktivira ih.
It works by attaching to receptors for a substance called glucagon-like peptide 1 (GLP-1), which are found on the surface of the cells in the pancreas and stimulate them to release insulin.
Djeluje vezujući se na receptore za djelatnu tvar peptid-1 nalik glukagonu (GLP-1), koji se nalaze na površini stanica u gušterači i stimuliraju ih za otpuštanje hormona.
Trulicity is available as prefilled pens (0.75 mg and 1.5 mg) containing a solution to be injected under the skin.
Trulicity je dostupan u napunjenim brizgalicama (0,75 mg i 1,5 mg) koje sadrže otopinu za potkožno ubrizgavanje.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Trulicity, including the appropriate precautions to be followed by healthcare professionals and patients.
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Trulicity nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
However, when used alone in patients who cannot take metformin, or when used in very elderly patients (aged over 75), the ratio of benefit to risk was greatest at the lower dose.
No, ako se koristio kao monoterapija u bolesnika koji ne mogu uzimati metformin, ili ako se koristio u vrlo starih bolesnika (starijih od 75 godina), omjer koristi i rizika bio je najveći u manjoj dozi.
After 26 weeks of treatment, Trulicity reduced HbA1c by between 0.71 and 1.59 percentage points at the lower dose, and by between 0.78 and 1.64 percentage points at the higher dose.
Nakon 26 tjedana liječenja, lijek Trulicity smanjio je vrijednosti HbA1c za između 0,71 i 1,59 postotnih bodova u manjoj dozi, te između 0,78 i 1,64 postotnih bodova u većoj dozi.
About 51% of those given the lower dose and 60% of patients given the higher dose of Trulicity achieved a target HbA1c below 7.0% and this was generally more than the proportion achieving this target with alternative treatments.
Otprilike 51 % bolesnika koji su primili manju dozu i 60 % bolesnika koji su primili veću dozu lijeka Trulicity postiglo je ciljanu vrijednost HbA1c manju od 7,0 %, a to je bilo načelno više u odnosu na udio koji je postigao ovu ciljanu vrijednost s alternativnim terapijama.
Trulicity was more effective than metformin at reducing HbA1c levels when used alone, and was more effective than the diabetes medicines exenatide (given twice daily) or sitagliptin, and at least as good as insulin glargine, when used as add-on to other treatments.
Trulicity je bio djelotvorniji od metformina u snižavanju razina HbA1c u slučajevima kada se koristio kao monoterapija, te je bio djelotvorniji od lijeka dijabetesa eksenatida (koji se primjenjivao dva puta dnevno) ili sitagliptina, te je bio barem podjednako dobar kao inzulin glargin kada se koristio kao dodatak drugim terapijama.
Trulicity contains the active substance dulaglutide.
Trulicity sadrži djelatnu tvar dulaglutid.
The medicine was more effective at weekly doses of 1.5 mg than 0.75 mg.
Lijek je bio djelotvorniji u tjednim dozama od 1,5 mg nego od
It can also be used as an ‘add-on' to other diabetes medicines, including insulin, when these medicines together with exercise and diet are not providing adequate control of blood glucose.
Može se također koristiti kao dodatak drugim lijekovima protiv dijabetesa, uključujući i inzulin, kada ti lijekovi zajedno s tjelovježbom i odgovarajućom prehranom ne pružaju primjerenu kontrolu razina glukoze u krvi.
The recommended dose is 0.75 mg injected once a week when used on its own, and 1.5 mg once a week in combination with other diabetes medicines (although doctors may begin with the lower dose in patients at potentially greater risk such as those aged over 75).
Preporučena doza je 0,75 mg ubrizgana jednom tjedno ako se lijek koristi kao monoterapija, te 1,5 mg jednom tjedno u kombinaciji s drugim lijekovima protiv dijabetesa (iako liječnici mogu početi s manjom dozom
Type 2 diabetes is a disease in which the pancreas does not make enough insulin to control the level of glucose in the blood or when the body is unable to use insulin effectively.
Dijabetes tipa 2 je bolest kod koje gušterača ne luči dovoljno inzulina za potrebe kontrole razine u krvi ili kada tijelo ne može učinkovito iskoristiti inzulin.
In these studies Trulicity was compared with placebo (a dummy treatment) or with other diabetes medicines when used alone or as an add-on to various combination treatments.
U tim ispitivanjima lijek Trulicity uspoređen je s placebom (prividnim liječenjem) ili s drugim lijekovima protiv dijabetesa ako se koristi kao monoterapija ili kao dodatak raznim kombiniranim liječenjima.
Trulicity is a diabetes medicine used in adults with type 2 diabetes to control their blood glucose (sugar) level.
Trulicity je lijek protiv šećerne bolesti koji se koristi za liječenje odraslih osoba s dijabetesom tipa 2 za kontroliranje razina glukoze (šećera) u krvi.
This causes the release of insulin and helps to reduce blood glucose levels and control type 2 diabetes.
To uzrokuje otpuštanje inzulina i pomaže u snižavanju razina glukoze u krvi te kontroli dijabetesa tipa 2.
For more information about treatment with Trulicity, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Više informacija o terapiji lijekom Trulicity pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svom liječniku ili ljekarniku.
How does Trulicity work?
Kako djeluje Trulicity?
Trulicity can be used on its own in patients whose blood glucose levels are not satisfactorily controlled on diet and exercise alone and who cannot take metformin (another diabetes medicine).
Trulicity se može koristiti kao monoterapija u bolesnika čije se razine glukoze ne mogu zadovoljavajuće kontrolirati prehranom i tjelovježbom te koji ne mogu uzimati metformin (drugi lijek protiv dijabetesa).
What benefits of Trulicity have been shown in studies?
Koje su koristi lijeka Trulicity utvrđene u ispitivanjima?
For the full list of all side effects and restrictions with Trulicity, see the package leaflet.
Potpuni popis nuspojava i ograničenja zabilježenih pri primjeni lijeka Trulicity potražite u uputi o lijeku.
For practical information about using Trulicity, patients should read the package leaflet or contact their doctor or pharmacist.
Praktične informacije o korištenju lijeka Trulicity pročitajte u uputi o lijeku, odnosno obratite se svom liječniku ili ljekarniku.
How is Trulicity used?
Kako se Trulicity koristi?
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom with a type of diabetes medicine called a sulphonylurea or with insulin, the dose of the sulphonylurea or insulin may need to be lowered to avoid hypoglycaemia (low blood sugar levels).
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom u bolesnika koji su potencijalno izloženi većem riziku poput primjerice onih starijih od 75 godina).
340 ml (0.5 mg/ml) 1 bottle + 2 syringes + 1 bottle adapter
1 boca + 2 štrcaljke + 1 nastavak za bočicu
Oral suspension Oral use bottle (PET)
Oralna suspenzija